Pharmaceutical Partnership Deal Terminations - GBI Research Reports

Pharmaceutical Partnership Deal Terminations

Pharmaceutical Partnership Deal Terminations - GBI Research Reports
Pharmaceutical Partnership Deal Terminations
Published Sep 01, 2011
119 pages — Published Sep 01, 2011
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GBI Research, the leading business intelligence provider, has released its latest report, Pharmaceutical Partnership Deal Terminations which provides key data, information and analysis of the major deals terminated in pharma industry in the period January, 2010, to June, 2011. The report provides a comprehensive insight into the partner companies involved in the deal, the licensed product and its clinical trial data, terms and conditions of the deal and deal value, and reason for deal termination. The report discusses the most common reasons for the termination of deals in the pharma industry. The report also provides an analysis of the therapeutic areas and the range of deal values of the terminated deals.

The most common reason for the termination of partnership deals was a change in company strategy, often due to a companys merger or acquisition activities, or due to a revision of its existing product pipeline. Other causes for the termination of deals included negative results in clinical trials designed to evaluate the safety and efficacy of the drug, delay in drug development, caused by rejection of a Marketing Authorization Application (MAA) or New Drug Application (NDA) by the regulatory authorities, increasing development costs of drug candidates, and disagreement between the licensor and licensee. The majority of terminated deals were in the therapeutic areas of CNS and infectious diseases. Also, most of the terminated deals had a deal value between $400m and $600m.

This report is built using data and information sourced from proprietary databases and secondary research and in-house analysis by GBI Researchs team of industry experts.

Scope

- The report analyzes the major deals terminated in the pharma industry in the period January, 2010, to June 2011, along with the licensed products, major reasons for deal terminations and therapeutic areas and the deal values of terminated deals.
- Comparative analysis of the causes, therapeutic areas and deal values of major terminated deals in the period January 2010, to June 2011
- Detailed description of the top 20 terminated licensing deals by deal value in the period January 2010, to June 2011
- For each deal, this description includes analysis of partner companies, licensed product description, a deal overview with terms and conditions, deal value and the reason for deal termination
- Geographies: Global

Reasons to buy

The report will enhance your decision making capability in a rapid and time-sensitive manner. It will -
- Allow you to understand the reasons behind termination of the major deals in the pharma industry in since January 2010.
- Provide you with the critical details of major terminated deals regarding the companies involved, the nature of licensed product and its clinical development, and the terms and conditions of the deal and deal values, among other things.
- It will allow you to develop effective strategies to avoid situations that would lead to the termination of a licensing or partnership deal by your company.

  
Source:
Document ID
GBIHC159MR
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents37
  List of Tables63
  List of Figures91
Top Partnership Deal Terminations Introduction102
  Licensing Agreement An Authorization101
  Termination of Licensing Agreements101
  GBI Research Report Guidance111
Top Partnership Deal Terminations Trends124
  Reasons for Deal Terminations121
  Therapeutic Areas Terminated Deals131
  Deal Values Terminated Deals142
Top Partnership Deal Terminations - Deals1699
  GlaxoSmithKline Terminates Licensing Agreement with Actelion for Almorexant161
    Companies Overview161
      GlaxoSmithKline161
      Actelion171
    Product Overview171
      Clinical Trial Details181
    Deal Overview191
      Deal Value191
      Deal Rationale191
    Reason for Termination201
  GlaxoSmithKline Terminates Co-Development Agreement with Targacept for Development of Neuronal Nicotinic Receptor Therapeutics201
    Companies Overview211
      GlaxoSmithKline211
      Targacept211
    Product Overview211
      Clinical Trial Details - TC-2696221
      Clinical Trial Details TC-6499221
    Deal Overview231
      Deal Value231
      Deal Rationale231
    Reason for Termination231
  Shire Terminates Licensing Agreement with Renovo Group for Juvista241
    Companies Overview241
      Shire Plc241
      Renovo Group Plc251
    Product Overview261
      Clinical Trial Details262
    Deal Overview281
      Deal Value281
      Deal Rationale281
    Reason for Termination281
  Anacor Pharmaceuticals Terminates Licensing Agreement with Merck for AN2690291
    Companies Overview291
      Anacor Pharmaceuticals291
      Merck &Co., Inc.301
    Product Overview311
      Clinical Trial Details313
    Deal Overview341
      Deal Value341
      Deal Rationale341
    Reason for Termination341
  Novartis Terminates Licensing Agreement with Human Genome Sciences for Albuferon351
    Companies Overview351
      Novartis AG351
      Human Genome Sciences, Inc.361
    Product Overview371
      Clinical Trial Details371
    Deal Overview381
      Deal Value381
      Deal Rationale381
    Reason for Termination391
  InterMune Terminates Licensing Agreement with F. Hoffmann-La Roche for ITMN-191391
    Companies Overview401
      InterMune, Inc.401
      F. Hoffmann-La Roche Ltd.402
    Product Overview421
      Clinical Trial Details421
    Deal Overview431
      Deal Value441
      Deal Rationale441
    Reason for Termination441
  GTx Terminates Worldwide Licensing Agreement with Merck for Ostarine451
    Companies Overview451
      GTx, Inc.451
      Merck &Co., Inc.461
    Product Overview461
      Clinical Trial Details462
    Deal Overview481
      Deal Value481
      Deal Rationale481
    Reason for Termination481
  Aveo Pharmaceuticals Terminates Licensing Agreement with Merck for AV-299491
    Companies Overview491
      Aveo Pharmaceuticals, Inc.491
      Merck &Co.491
    Product Overview501
      Clinical Trial Details512
    Deal Overview531
      Deal Value531
      Deal Rationale531
    Reason for Termination531
  Merck KGaA Terminates Worldwide Licensing Agreement with Lpath for Asonep541
    Companies Overview541
      Merck KGaA541
      Lpath, Inc.551
    Product Overview561
      Clinical Trial Details561
    Deal Overview571
      Deal Value571
      Deal Rationale571
    Reason for Termination571
  Portola Pharmaceuticals Terminates Licensing Agreement with Merck for Betrixaban581
    Companies Overview581
      Portola Pharmaceuticals, Inc.581
      Merck &Co.581
    Product Overview591
      Clinical Trial Details592
    Deal Overview611
      Deal Value611
      Deal Rationale611
    Reason for Termination611
  Celldex Therapeutics Terminates Licensing Agreement with Pfizer for Rindopepimut621
    Companies Overview621
      Celldex Therapeutics, Inc621
      Pfizer Inc.631
    Product Overview631
      Clinical Trial Details642
    Deal Overview661
      Deal Value661
      Deal Rationale661
    Reason for Termination661
  Depomed Terminates Licensing Agreement with Abbott Laboratories for DM-1796671
    Companies Overview671
      Depomed Inc.671
      Abbott Laboratories682
    Product Overview701
      Clinical Trial Details703
    Deal Overview731
      Deal Value731
      Deal Rationale731
    Reason for Termination731
  Sanofi Terminates Licensing Agreement with Metabolex for MBX-2982741
    Companies Overview741
      Sanofi741
      Metabolex, Inc.751
    Product Overview751
      Clinical Trial Details751
    Deal Overview761
      Deal Value761
      Deal Rationale761
    Reason for Termination761
  BioLineRx Terminates Licensing Agreement with Cypress Bioscience for BL-1020771
    Companies Overview781
      BioLineRx, Ltd.781
      Cypress Bioscience, Inc.781
    Product Overview791
      Clinical Trial Details793
    Deal Overview821
      Deal Value821
      Deal Rationale821
    Reason for Termination831
  Cilag Terminates Licensing Agreement with Basilea Pharmaceutica for Ceftobiprole831
    Companies Overview841
      Janssen-Cilag EMEA841
      Basilea Pharmaceutica Ltd.841
    Product Overview851
      Clinical Trial Details851
    Deal Overview861
      Deal Value861
      Deal Rationale861
    Reason for Termination871
  Roche Terminates Licensing Agreement with Ipsen for Taspoglutide871
    Companies Overview881
      F. Hoffmann-La Roche Ltd.881
      Ipsen S.A.881
    Product Overview881
      Clinical Trial Details887
    Deal Overview951
      Deal Value951
      Deal Rationale951
    Reason for Termination951
  Roche Terminates Licensing Agreement with Transgene for Papilloma Vaccine TG4001961
    Companies Overview961
      Transgene SA961
      F. Hoffmann-La Roche Ltd.961
    Product Overview971
      Clinical Trial Details971
    Deal Overview971
      Deal Value971
      Deal Rationale981
    Reason for Termination981
  Rigel Pharmaceuticals Terminates Licensing Agreement with Pfizer for R343981
    Companies Overview991
      Rigel Pharmaceuticals, Inc.991
      Pfizer Inc.991
    Product Overview1001
      Clinical Trial Details1001
    Deal Overview1001
      Deal Value1001
      Deal Rationale1001
    Reason for Termination1001
  Abbott Laboratories Terminates Licensing Agreement with SkyePharma for Flutiform1011
    Companies Overview1021
      Abbott Laboratories1021
      SkyePharma PLC1021
    Product Overview1031
      Clinical Trial Details1035
    Deal Overview1081
      Deal Value1081
      Deal Rationale1081
    Reason for Termination1081
  Merck Terminates Strategic Alliance with Intercell for V7101091
    Companies Overview1091
      Intercell AG1091
      Merck &Co., Inc.1101
    Product Overview1101
      Clinical Trial Details1104
    Deal Overview1141
      Deal Value1141
      Deal Rationale1141
    Reason for Termination1141
Top Partnership Deal Terminations - Appendix1155
  Market Definitions1151
  Abbreviations1152
  Research Methodology1173
    Coverage1171
    Secondary Research1181
    Primary Research1181
    Section-wise Research Methodology1181
      Trends1181
      Deals1191
    Expert Panel Validation1191
  Contact Us1191
  Disclaimer1191
  Sources1191

Table Of Contents

GBI Research Reports—GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders' insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs.

About the Author


Cite this Report

  
MLA:
GBI Research Reports. "Pharmaceutical Partnership Deal Terminations" Sep 01, 2011. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Pharmaceutical-Partnership-Deal-Terminations-2115-254>
  
APA:
GBI Research Reports. (2011). Pharmaceutical Partnership Deal Terminations Sep 01, 2011. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GBI-Research-Reports/Pharmaceutical-Partnership-Deal-Terminations-2115-254>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.